USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NANOTHERAPEUTICS, INC.
Address:
13859 Progress Blvd.
ALACHUA, FL
Phone:
(386) 462-9663
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,809,993.00 10
SBIR Phase II $2,371,112.00 4
STTR Phase I $99,705.00 1

Award List:

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$98,000.00
Agency:
HHS
Principal Investigator:
James Talton
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$98,000.00
Agency:
HHS
Principal Investigator:
James D. Talton
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$70,000.00
Agency:
NASA
Principal Investigator:
Abstract:
N/a

Novel Dry-Powder Coatings for Low-G Inhalation Therapy

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$538,071.00
Agency:
NASA
Principal Investigator:
James 1. Ph.D., President
Abstract:
Currently, dry-powder inhalers (DPI) are used to deliver various drugs to the lungs for localized or systemic delivery. Although current inhaled formulations are adequate for pulmonary drug therapy under normal gravity, inhalation therapies on earth and potentially in space are plagued by low… More

Novel Dry-Powder Coatings for Low-G Inhalation Therapy

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
NASA
Principal Investigator:
James 1. Ph.D., President
Abstract:
Currently, dry-powder inhalers (DPI) are used to deliver various drugs to the lungs for localized or systemic delivery. Although current inhaled formulations are adequate for pulmonary drug therapy under normal gravity, inhalation therapies on earth and potentially in space are plagued by low… More

Oral Therapy using Anti-Oxidants for Alzheimer's Disease

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,816.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Nanotherapeutics proposes to evaluate oral taurine therapy for Alzheimer's disease (AD). AD, the most common form of dementia among older people, affects over 4 million Americans. It requires full-time care in the end stages and is a significant financial burden… More

ORAL BUPRENORPHINE NANOPARTICLE FORMULATION

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$98,838.00
Agency:
HHS
Principal Investigator:
James Talton
Abstract:
N/a

Technologies to Defeat Improvised Explosive Devices (IED's)

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$99,745.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
James Talton, President and CEO
Abstract:
In this Phase I SBIR Proposal, Nanotherapeutics, Inc. proposes to demonstrate the improved proximity detection of hexamethylene triperoxidediamine (HMTD) and triacetone triperoxide (TATP) explosives using its proprietary NanobreathTM preconcentrator and 4-SAW array. The NanobreathTM 4-SAW Array, a… More

Antimicrobial Bone Graft Substitute

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$69,938.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
James D. Talton, President and CEO
Abstract:
In this Phase I SBIR project, Nanotherapeutics proposes to utilize its proprietary particle delivery systems to develop an injectable bone paste formulation incorporating an anti-microbial (PHMB) as a bone graft substitute. A solution-based system, GraftonT (Osteotech) and, recently, a dry… More

ORAL BUPRENORPHINE NANOPARTICLE FORMULATION

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$775,506.00
Agency:
HHS
Principal Investigator:
James Talton
Abstract:
N/a

Technologies to Defeat Improvised Explosive Devices (IED's)

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$940,875.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Abstract:
The overall goal of this Phase II project is to develop the Nanobreathr detection system for proximity detection of explosives at 50 meters, and specifically detection of peroxide improvised explosive devices (IED's) such as TATP and HMTD. Pentagon statistics show that about half the U.S. battle… More

ORAL BUPRENORPHINE NANOPARTICLE FORMULATION

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$116,660.00
Agency:
HHS
Principal Investigator:
Abstract:
Not Available

Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$595,945.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant) Typhoid fever is a major cause of morbidity worldwide with an estimated incidence of 16 to 33 million infections and 500,000 to 600,000 deaths annually. It is caused by Salmonella typhi (S. typhi). The Vi capsular polys accharide of S. typhi is the protective… More

GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$578,711.00
Agency:
HHS
Principal Investigator:
James F. Kirk – 386-462-9663
Abstract:
DESCRIPTION (provided by applicant): Noroviruses are a group of enteropathogenic viruses belonging to the taxonomic family Caliciviridae, which causes approximately 90% of epidemic non-bacterial outbreaks of gastroenteritis around the world and may be responsible for 50% of all foodborne outbreaks… More